1. Riluzole-induced Lung Injury in Two Patients with Amyotrophic Lateral Sclerosis
- Author
-
Masamitsu Tatewaki, Sayo Soda, Yasutsugu Fukushima, Takuya Kakuta, Hirokuni Hirata, Honma Koichi, Takeshi Fukuda, Kazuyuki Chibana, Masafumi Arima, Mineaki Watanabe, Kumiya Sugiyama, Fumiya Fukushima, and Taichi Shiobara
- Subjects
Pathology ,medicine.medical_specialty ,Prednisolone ,Lung biopsy ,Lung injury ,Ground-glass opacity ,Internal Medicine ,medicine ,Humans ,Amyotrophic lateral sclerosis ,Diffuse alveolar damage ,Aged ,Aged, 80 and over ,Riluzole ,medicine.diagnostic_test ,business.industry ,Amyotrophic Lateral Sclerosis ,Lung Injury ,General Medicine ,respiratory system ,medicine.disease ,respiratory tract diseases ,Neuroprotective Agents ,Bronchoalveolar lavage ,Female ,medicine.symptom ,business ,Vasculitis ,Excitatory Amino Acid Antagonists ,medicine.drug - Abstract
Riluzole has recently been proven as the first effective drug for the treatment of amyotrophic lateral sclerosis (ALS). We report two rare cases of lung injury caused by riluzole therapy in patients with ALS. Chest radiographs showed bilateral lower lobe, dorsal-dominant ground glass opacity, and/or consolidation. A drug lymphocyte stimulation test (DLST) of peripheral blood or bronchoalveolar lavage cells was positive for riluzole. Histopathological examination of lung biopsy specimens revealed lung injury without fungoid granuloma, vasculitis, or diffuse alveolar damage. To the best of our knowledge, this is the first report of riluzole-induced lung injury with positive DLST results.
- Published
- 2012
- Full Text
- View/download PDF